What is the current market size and future outlook for the bacterial vaginosis market?
The bacterial vaginosis market size has grown strongly in recent years. It will grow from $3.03 billion in 2024 to $3.32 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increase adoption of point-of-care diagnostics, growth of e-commerce, increase in risky sexual behaviors, rise in STI vaccination, and increase in healthcare access.
The bacterial vaginosis market size is expected to see strong growth in the next few years. It will grow to $4.75 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing prevalence of bacterial vaginosis, rising demand for functional foods, increasing incidence of STIs, increasing prevalence of women’s health conditions, and rising awareness of menopause. Major trends in the forecast period include integration of artificial intelligence (ai) in diagnostics, adoption of probiotics, advancements in home-based STI testing, and adoption of sustainable materials in women’s health devices.
Get Your Free Sample of The Global Bacterial Vaginosis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21110&type=smp
How has the bacterial vaginosis market evolved, and what factors have shaped its growth?
The increasing incidence of sexually transmitted infections (STIs) is expected to drive the growth of the bacterial vaginosis market going forward. Sexually transmitted infections (STIs) refer to infections that are primarily spread through sexual contact. These infections can be caused by bacteria, viruses, or parasites. The increasing incidence of STIs is due to factors such as unprotected sex, multiple partners, lack of awareness, and antibiotic resistance. Bacterial vaginosis increases susceptibility to STIs by disrupting the vaginal bacterial balance, making it easier for infections such as HIV and chlamydia to take hold. For instance, in March 2024, according to the European Centre for Disease Prevention and Control (ECDC), a Sweden-based government agency, in 2022, there was a significant increase in reported cases compared to the previous year, with gonorrhea rising by 48%, syphilis by 34%, and chlamydia by 16%. Therefore, the increasing incidence of sexually transmitted infections (STIs) is driving the growth of the bacterial vaginosis market.
What are the major segments of the bacterial vaginosis market?
The bacterial vaginosis market covered in this report is segmented –
1) By Type: Point-Of-Care Testing, Laboratory Testing, Other Types
2) By Product: Below 15 Years, Between 15-45, Other Products
3) By Application: Antibiotics, Other Applications
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Point-Of-Care Testing: Rapid Diagnostic Tests, Microscopy-based Tests, Immunoassays
2) By Laboratory Testing: Gram Staining, Polymerase Chain Reaction (PCR), DNA Probe Tests, Culture-based Testing
3) By Other Types: Home Testing Kits, Enzyme-linked Immunosorbent Assay (ELISA)
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/bacterial-vaginosis-global-market-report
Which companies dominate the bacterial vaginosis market?
Major companies operating in the bacterial vaginosis market are Pfizer Inc., Merck & Co. Inc., Merck KGaA, Bayer AG, Sanofi SA, Thermo Fisher Scientific, Becton Dickinson, Viatris Inc., Otsuka Pharmaceutical, LabCorp, Quest Diagnostics, Organon & Co., UT Southwestern Medical Center, Hologic Inc., bioMérieux SA, Shionogi & Company Limited, Melinta Therapeutics Inc., Evofem Biosciences, Gedea Biotech, Fleurstat, Medical Diagnostic Laboratories
How will evolving trends contribute to the growth of the bacterial vaginosis market?
Major companies operating in the bacterial vaginosis market are focusing on developing innovative solutions such as multiplexed polymerase chain reaction (PCR) tests to enhance the speed of diagnosis and treatment. A multiplexed PCR test refers to a type of polymerase chain reaction (PCR) test that allows the simultaneous amplification and detection of multiple target DNA or RNA sequences in a single PCR experiment. For instance, in November 2022, Cepheid, a US-based biotechnology research company, introduced the Xpert Xpress Multiplex Vaginal Panel (MVP). This panel provides rapid results in under 60 minutes and detects three vaginal infections—bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis (TV) from a single sample. It supports both clinician-collected and self-collected swabs, leveraging automated real-time PCR technology to enhance diagnostic accuracy and improve treatment outcomes for women. Its versatility allows for use in various clinical settings, ensuring efficient and precise detection of vaginal infections.
What are the key regional dynamics of the bacterial vaginosis market, and which region leads in market share?
North America was the largest region in the bacterial vaginosis market in 2024. The regions covered in the bacterial vaginosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Bacterial Vaginosis Market Report 2025 Offer?
The bacterial vaginosis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Bacterial vaginosis (BV) is a common vaginal infection caused by an imbalance of naturally occurring bacteria, leading to a decrease in lactobacilli and an overgrowth of anaerobic bacteria. It is characterized by symptoms such as a fishy odor, thin grayish-white discharge, and vaginal discomfort, though some cases may be asymptomatic.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21110
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
